F025 Advanced Dermoscopy
DESCRIPTION
Open admission to eligible categories, no tuition or ticket
This session aims to make the attendees familiar with practical evidence-based rules to minimize the risk of missing melanoma. The interpretation of dermatoscopic morphology of lesions located on special anatomic sites will be analyzed and complicated clinical scenarios will be discussed. The attendees will learn to analyze the dermatoscopic morphology of flat pigmented lesions on the face and recognize early lentigo maligna. They will also learn to discriminate among different causes of nail pigmentation. In addition, the evaluation of tumors located on other special sites including scalp, mucosa and acral sites will be discussed.
LEARNING OBJECTIVES
Discriminate early lentigo maligna from pigmented actinic keratosis and solar lentigo.
Differentiate among different causes of pigmented nail bands.
Evaluate lesions on other specific locations including acral sites, mucosa, scalp.
SCHEDULE
9:00 PM
7 rules not to miss melanoma reloaded
Aimilios Lallas, MD, MSc, PhD, IFAAD
9:20 PM
The most important rules not to miss scalp melanoma
Joseph Malvehy, MD, IFAAD
9:40 PM
The most important rules not to miss facial melanoma
Sebastian Podlipnik
10:00 PM
The most important rules not to miss acral melanoma
John Paoli, MD, PhD, IFAAD
10:20 PM
The most important rules not to miss nail melanoma
BENGU NISA Akay
10:40 PM
The most important rules not to miss mucosal melanoma
Susana Puig, MD, IFAAD
SPEAKERS
BENGU NISA Akay
Aimilios Lallas, MD, MSc, PhD, IFAAD
Joseph Malvehy, MD, IFAAD
John Paoli, MD, PhD, IFAAD
Sebastian Podlipnik
Susana Puig, MD, IFAAD
SPEAKER DISCLOSURES
BENGU NISA Akay
No financial relationships exist with ineligible companies.
Aimilios Lallas, MD, MSc, PhD, IFAAD
3Gen, LLC – Advisory Board(Equipment); Avène – Speaker/Faculty Education(Honoraria); Bioderma – Speaker(Honoraria); Elsevier Inc. – Other(Fees); Fotofinder – Advisory Board(Equipment); La Roche-Posay Laboratorie Pharmaceutique – Speaker/Faculty Education(Honoraria);
Joseph Malvehy, MD, IFAAD
3Gen, LLC – Investigator(Equipment); Almirall – Advisory Board(Fees); Athena tech – Founder(Stock Options); Canfield Scientific, Inc. – Advisory Board(Honoraria); Cedilp – Founder(Salary); Dermavision – Board of Directors(Fees); Dermavision Solutions – Board of Directors(Fees);
John Paoli, MD, PhD, IFAAD
No financial relationships exist with ineligible companies.
Sebastian Podlipnik
No financial relationships exist with ineligible companies.
Susana Puig, MD, IFAAD
Almirall – Advisory Board(Honoraria), Speaker(Fees); Amgen – Advisory Board(Honoraria); AThena tech s.l. – Founder(Stock Options); Athena Tech SL – Founder(Stock Options); Avène – Consultant(Honoraria), Speaker/Faculty Education(Honoraria); Bristol-Myers Squibb – Advisory Board(Honoraria), Investigator(Fees); Canfield Scientific, Inc. – Consultant(Honoraria); Cantabria – Other(Grants/Research Funding), Speaker(Honoraria); Dermavision Solutions – Stockholder Private Company(Stock Options); Diagnosis Dermatologica – Board of Directors(Honoraria); ISDIN – Other(Grants/Research Funding), Speaker(Honoraria); La Roche-Posay Laboratorie Pharmaceutique – Other(Grants/Research Funding), Speaker(Honoraria); La Roche-Posay Laboratoire Pharmaceutique – Advisory Board(Honoraria); Leo Pharma Inc – Advisory Board(Fees), Speaker(Honoraria); Lucid, Inc. – Investigator(Equipment); Novartis – Other(Grants/Research Funding), Speaker/Faculty Education(Fees); Pfizer Inc. – Investigator(Honoraria), Other(Grants/Research Funding); Sanofi – Advisory Board(Honoraria); Sanofi/Regeneron – Speaker/Faculty Education(Fees); Taylor & Francis – Other(Patent royalties or other compensation for Intellectual Property Rights);